<DOC>
	<DOC>NCT00434642</DOC>
	<brief_summary>This was a placebo-controlled, randomized, multicenter Phase III study that evaluated the safety and efficacy of bevacizumab, administered in combination with carboplatin with gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.</brief_summary>
	<brief_title>A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed Informed Consent Form Age â‰¥ 18 years Documented ovarian, primary peritoneal, or fallopian tube carcinoma that has recurred No prior chemotherapy in the recurrent setting Measurable disease Recovered from prior radiation therapy or surgery Prior chemotherapy treatment for recurrent ovarian, primary peritoneal, or fallopian tube carcinoma History of abdominal fistula, gastrointestinal perforation (GIP), or intraabdominal abscess Patients with clinical symptoms or signs of gastrointestinal (GI) obstruction or who require parenteral hydration, parenteral nutrition, or tube feeding Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure Current, recent, or planned participation in an experimental drug study History of systemic bevacizumab (Avastin) or other vascular endothelial growth factor (VEGF) or VEGF receptortargeted agent use Inadequately controlled hypertension Prior history of hypertensive crisis or hypertensive encephalopathy New York Heart Association Class II or greater congestive heart failure (CHF) History of myocardial infarction or unstable angina History of stroke or transient ischemic attack (TIA) Known central nervous system (CNS) disease except for treated brain metastasis Significant vascular disease or recent peripheral arterial thrombosis History of hemoptysis Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Avastin</keyword>
	<keyword>Ovarian carcinoma</keyword>
	<keyword>Peritoneal carcinoma</keyword>
	<keyword>Peritoneal cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Fallopian tube carcinoma</keyword>
	<keyword>OCEANS</keyword>
</DOC>